{
    "xml": "<topic id=\"PHP34620\" outputclass=\"drugClass\" rev=\"1.18\" type=\"drugClass\" namespace=\"/drug-classes/bisphosphonates\" basename=\"bisphosphonates\" title=\"BISPHOSPHONATES\">\n<title>BISPHOSPHONATES </title>\n<topic id=\"PHP57212\" outputclass=\"drugAction\" rev=\"1.6\" parent=\"/drug-classes/bisphosphonates\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Bisphosphonates are adsorbed onto hydroxyapatite crystals in bone, slowing both their rate of growth and dissolution, and therefore reducing the rate of bone turnover.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57220\" outputclass=\"importantSafetyInformation\" rev=\"1.32\" parent=\"/drug-classes/bisphosphonates\">\n<title>Important safety information</title>\n<body>\r\n<section>\r\n<sectiondiv>\r\n<p outputclass=\"title\">MHRA/CHM advice: Bisphosphonates: atypical femoral fractures (June 2011)</p>\r\n<p>Atypical femoral fractures have been reported rarely with bisphosphonate treatment, mainly in patients receiving long-term treatment for osteoporosis.</p>\r\n<p>The need to continue bisphosphonate treatment for osteoporosis should be re-evaluated periodically based on an assessment of the benefits and risks of treatment for individual patients, particularly after 5 or more years of use.</p>\r\n<p>Patients should be advised to report any thigh, hip, or groin pain during treatment with a bisphosphonate.</p>\r\n<p>Discontinuation of bisphosphonate treatment in patients suspected to have an atypical femoral fracture should be considered after an assessment of the benefits and risks of continued treatment.</p>\n</sectiondiv>\r\n<sectiondiv>\r\n<p outputclass=\"title\">MHRA/CHM advice: Bisphosphonates: osteonecrosis of the jaw (November 2009) and Intravenous bisphosphonates: osteonecrosis of the jaw&#8212;further measures to minimise risk (July 2015)</p>\r\n<p>The risk of osteonecrosis of the jaw is substantially greater for patients receiving intravenous bisphosphonates in the treatment of cancer than for patients receiving oral bisphosphonates for osteoporosis or Paget&#8217;s disease.</p>\r\n<p>Risk factors for developing osteonecrosis of the jaw that should be considered are: potency of bisphosphonate (highest for zoledronate), route of administration, cumulative dose, duration and type of malignant disease, concomitant treatment, smoking, comorbid conditions, and history of dental disease.</p>\r\n<p>All patients should have a dental check-up (and any necessary remedial work should be performed) before bisphosphonate treatment, or as soon as possible after starting treatment. Patients should also maintain good oral hygiene, receive routine dental check-ups, and report any oral symptoms such as dental mobility, pain, or swelling, non-healing sores or discharge to a doctor and dentist during treatment.</p>\r\n<p>Before prescribing an intravenous bisphosphonate, patients should be given a patient reminder card and informed of the risk of osteonecrosis of the jaw. Advise patients to tell their doctor if they have any problems with their mouth or teeth before starting treatment, and if the patient wears dentures, they should make sure their dentures fit properly. Patients should tell their doctor and dentist that they are receiving an intravenous bisphosphonate if they need dental treatment or dental surgery.</p>\r\n<p>Guidance for dentists in primary care is included in <i>Oral Health Management of Patients Prescribed Bisphosphonates: Dental Clinical Guidance</i>, Scottish Dental Clinical Effectiveness Programme, April 2011 (available at <xref format=\"html\" href=\"http://www.sdcep.org.uk\">www.sdcep.org.uk</xref>).</p>\n</sectiondiv>\n</section>\r\n</body>\n</topic>\n<topic id=\"PHP57138\" outputclass=\"patientAndCarerAdvice\" rev=\"1.12\" parent=\"/drug-classes/bisphosphonates\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"title\">Atypical femoral fractures</p>\n<p>Patients should be advised to report any thigh, hip, or groin pain during treatment with a bisphosphonate.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Osteonecrosis of the jaw</p>\n<p>During bisphosphonate treatment patients should maintain good oral hygiene, receive routine dental check-ups, and report any oral symptoms.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugClasses\" href=\"#drugClasses\" title=\"Drug classes\" namespace=\"/drug-classes\">Drug classes</xref>\n</parents>\n<drugs>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP4656\" title=\"ALENDRONIC ACID\" namespace=\"/drugs/alendronic-acid\">ALENDRONIC ACID</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP4668\" title=\"PAMIDRONATE DISODIUM\" namespace=\"/drugs/pamidronate-disodium\">PAMIDRONATE DISODIUM</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP4671\" title=\"IBANDRONIC ACID\" namespace=\"/drugs/ibandronic-acid\">IBANDRONIC ACID</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP4675\" title=\"RISEDRONATE SODIUM\" namespace=\"/drugs/risedronate-sodium\">RISEDRONATE SODIUM</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP4681\" title=\"SODIUM CLODRONATE\" namespace=\"/drugs/sodium-clodronate\">SODIUM CLODRONATE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP4687\" title=\"ZOLEDRONIC ACID\" namespace=\"/drugs/zoledronic-acid\">ZOLEDRONIC ACID</xref>\n</drugs>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#drugClasses\" href=\"#drugClasses\" namespace=\"/drug-classes\" title=\"Drug classes\" count=\"1\" rel=\"link\">Drug classes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP4656\" namespace=\"/drugs/alendronic-acid\" title=\"ALENDRONIC ACID\" count=\"1\" rel=\"link\">ALENDRONIC ACID</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP4668\" namespace=\"/drugs/pamidronate-disodium\" title=\"PAMIDRONATE DISODIUM\" count=\"1\" rel=\"link\">PAMIDRONATE DISODIUM</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP4671\" namespace=\"/drugs/ibandronic-acid\" title=\"IBANDRONIC ACID\" count=\"1\" rel=\"link\">IBANDRONIC ACID</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP4675\" namespace=\"/drugs/risedronate-sodium\" title=\"RISEDRONATE SODIUM\" count=\"1\" rel=\"link\">RISEDRONATE SODIUM</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP4681\" namespace=\"/drugs/sodium-clodronate\" title=\"SODIUM CLODRONATE\" count=\"1\" rel=\"link\">SODIUM CLODRONATE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP4687\" namespace=\"/drugs/zoledronic-acid\" title=\"ZOLEDRONIC ACID\" count=\"1\" rel=\"link\">ZOLEDRONIC ACID</xref>\n</links>\n</topic>",
    "id": "PHP34620",
    "outputclass": "drugClass",
    "rev": "1.18",
    "type": "drugClass",
    "namespace": "/drug-classes/bisphosphonates",
    "basename": "bisphosphonates",
    "title": "BISPHOSPHONATES",
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Bisphosphonates are adsorbed onto hydroxyapatite crystals in bone, slowing both their rate of growth and dissolution, and therefore reducing the rate of bone turnover.",
                "html": "<p>Bisphosphonates are adsorbed onto hydroxyapatite crystals in bone, slowing both their rate of growth and dissolution, and therefore reducing the rate of bone turnover.</p>"
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "MHRA/CHM advice: Bisphosphonates: atypical femoral fractures (June 2011)",
                "textContent": "Atypical femoral fractures have been reported rarely with bisphosphonate treatment, mainly in patients receiving long-term treatment for osteoporosis.\n\nThe need to continue bisphosphonate treatment for osteoporosis should be re-evaluated periodically based on an assessment of the benefits and risks of treatment for individual patients, particularly after 5 or more years of use.\n\nPatients should be advised to report any thigh, hip, or groin pain during treatment with a bisphosphonate.\n\nDiscontinuation of bisphosphonate treatment in patients suspected to have an atypical femoral fracture should be considered after an assessment of the benefits and risks of continued treatment.",
                "html": "<p>Atypical femoral fractures have been reported rarely with bisphosphonate treatment, mainly in patients receiving long-term treatment for osteoporosis.</p><p>The need to continue bisphosphonate treatment for osteoporosis should be re-evaluated periodically based on an assessment of the benefits and risks of treatment for individual patients, particularly after 5 or more years of use.</p><p>Patients should be advised to report any thigh, hip, or groin pain during treatment with a bisphosphonate.</p><p>Discontinuation of bisphosphonate treatment in patients suspected to have an atypical femoral fracture should be considered after an assessment of the benefits and risks of continued treatment.</p>"
            },
            {
                "type": "importantSafetyInformation",
                "references": [
                    {
                        "id": "http://www.sdcep.org.uk",
                        "label": "www.sdcep.org.uk"
                    }
                ],
                "title": "MHRA/CHM advice: Bisphosphonates: osteonecrosis of the jaw (November 2009) and Intravenous bisphosphonates: osteonecrosis of the jaw&#8212;further measures to minimise risk (July 2015)",
                "textContent": "The risk of osteonecrosis of the jaw is substantially greater for patients receiving intravenous bisphosphonates in the treatment of cancer than for patients receiving oral bisphosphonates for osteoporosis or Paget&#8217;s disease.\n\nRisk factors for developing osteonecrosis of the jaw that should be considered are: potency of bisphosphonate (highest for zoledronate), route of administration, cumulative dose, duration and type of malignant disease, concomitant treatment, smoking, comorbid conditions, and history of dental disease.\n\nAll patients should have a dental check-up (and any necessary remedial work should be performed) before bisphosphonate treatment, or as soon as possible after starting treatment. Patients should also maintain good oral hygiene, receive routine dental check-ups, and report any oral symptoms such as dental mobility, pain, or swelling, non-healing sores or discharge to a doctor and dentist during treatment.\n\nBefore prescribing an intravenous bisphosphonate, patients should be given a patient reminder card and informed of the risk of osteonecrosis of the jaw. Advise patients to tell their doctor if they have any problems with their mouth or teeth before starting treatment, and if the patient wears dentures, they should make sure their dentures fit properly. Patients should tell their doctor and dentist that they are receiving an intravenous bisphosphonate if they need dental treatment or dental surgery.\n\nGuidance for dentists in primary care is included in Oral Health Management of Patients Prescribed Bisphosphonates: Dental Clinical Guidance, Scottish Dental Clinical Effectiveness Programme, April 2011 (available at www.sdcep.org.uk).",
                "html": "<p>The risk of osteonecrosis of the jaw is substantially greater for patients receiving intravenous bisphosphonates in the treatment of cancer than for patients receiving oral bisphosphonates for osteoporosis or Paget&#8217;s disease.</p><p>Risk factors for developing osteonecrosis of the jaw that should be considered are: potency of bisphosphonate (highest for zoledronate), route of administration, cumulative dose, duration and type of malignant disease, concomitant treatment, smoking, comorbid conditions, and history of dental disease.</p><p>All patients should have a dental check-up (and any necessary remedial work should be performed) before bisphosphonate treatment, or as soon as possible after starting treatment. Patients should also maintain good oral hygiene, receive routine dental check-ups, and report any oral symptoms such as dental mobility, pain, or swelling, non-healing sores or discharge to a doctor and dentist during treatment.</p><p>Before prescribing an intravenous bisphosphonate, patients should be given a patient reminder card and informed of the risk of osteonecrosis of the jaw. Advise patients to tell their doctor if they have any problems with their mouth or teeth before starting treatment, and if the patient wears dentures, they should make sure their dentures fit properly. Patients should tell their doctor and dentist that they are receiving an intravenous bisphosphonate if they need dental treatment or dental surgery.</p><p>Guidance for dentists in primary care is included in <i>Oral Health Management of Patients Prescribed Bisphosphonates: Dental Clinical Guidance</i>, Scottish Dental Clinical Effectiveness Programme, April 2011 (available at <xref format=\"html\" href=\"http://www.sdcep.org.uk\">www.sdcep.org.uk</xref>).</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "title": "Atypical femoral fractures",
                "textContent": "Patients should be advised to report any thigh, hip, or groin pain during treatment with a bisphosphonate.",
                "html": "<p>Patients should be advised to report any thigh, hip, or groin pain during treatment with a bisphosphonate.</p>"
            },
            {
                "type": "generalPatientAdvice",
                "title": "Osteonecrosis of the jaw",
                "textContent": "During bisphosphonate treatment patients should maintain good oral hygiene, receive routine dental check-ups, and report any oral symptoms.",
                "html": "<p>During bisphosphonate treatment patients should maintain good oral hygiene, receive routine dental check-ups, and report any oral symptoms.</p>"
            }
        ]
    },
    "drugsInClass": [
        {
            "id": "PHP4656",
            "label": "ALENDRONIC ACID",
            "type": "drug"
        },
        {
            "id": "PHP4668",
            "label": "PAMIDRONATE DISODIUM",
            "type": "drug"
        },
        {
            "id": "PHP4671",
            "label": "IBANDRONIC ACID",
            "type": "drug"
        },
        {
            "id": "PHP4675",
            "label": "RISEDRONATE SODIUM",
            "type": "drug"
        },
        {
            "id": "PHP4681",
            "label": "SODIUM CLODRONATE",
            "type": "drug"
        },
        {
            "id": "PHP4687",
            "label": "ZOLEDRONIC ACID",
            "type": "drug"
        }
    ],
    "backlinks": {},
    "links": {
        "#drugClasses": [
            {
                "id": "drugClasses",
                "label": "Drug classes",
                "type": "#drugClasses"
            }
        ],
        "drug": [
            {
                "id": "PHP4656",
                "label": "ALENDRONIC ACID",
                "type": "drug"
            },
            {
                "id": "PHP4668",
                "label": "PAMIDRONATE DISODIUM",
                "type": "drug"
            },
            {
                "id": "PHP4671",
                "label": "IBANDRONIC ACID",
                "type": "drug"
            },
            {
                "id": "PHP4675",
                "label": "RISEDRONATE SODIUM",
                "type": "drug"
            },
            {
                "id": "PHP4681",
                "label": "SODIUM CLODRONATE",
                "type": "drug"
            },
            {
                "id": "PHP4687",
                "label": "ZOLEDRONIC ACID",
                "type": "drug"
            }
        ]
    }
}